GlaxoSmithKline (GSK) Commence $13/Share Tender Offer for Human Genome Sciences (HGSI)
Tweet
Share
E-mailGet Alerts GSK Hot Sheet
Join SI Premium – FREE
GlaxoSmithKline plc (NYSE: GSK) said it will not participate in Human Genome Sciences (NASDAQ: HGSI) strategic alternatives review process and will instead commence a tender offer this week to acquire all of the outstanding shares of HGS for US$13.00 per share in cash.
Shares of HGSI last closed at $14.62 in anticipation of a higher bid.
Shares of HGSI last closed at $14.62 in anticipation of a higher bid.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bernstein on whether Hershey (HSY) could eventually step up to buy Mondelez (MDLZ)
- Questor Technology signs LOI to acquire Emission Rx for up to C$3M
- Two Harbors receives final approval for CrossCountry Mortgage merger
Create E-mail Alert Related Categories
Mergers and Acquisitions, RumorsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
